Alliance for Pandemic Preparedness

June 1, 2021

Colchicine for Community-Treated Patients with COVID-19 (COLCORONA): A Phase 3, Randomised, Double-Blinded, Adaptive, Placebo-Controlled, Multicentre Trial

Category:

Topic:

Keywords (Tags):

  • The anti-inflammatory drug colchicine did not change the rate of hospital admission or death related to COVID-19 (a composite endpoint) in a phase 3 double-blind placebo-controlled trial among non-hospitalized patients diagnosed with COVID-19 either by PCR testing or clinical criteria (OR=0.79, 95%CI: 0.61-1.03). The primary endpoint occurred in 4.7% (104 of 2,235) patients in the colchicine group and in 5.8% (131 of 2,253) of patients in the placebo group. Among those with PCR-confirmed COVID-19 (n=4,159), the primary endpoint occurred in 4.6% in the colchicine group vs 6.0% in the placebo group (OR=0.75, 95%CI: 0.57-0.99). Pneumonia occurred in fewer patients in the colchicine group (2.9% vs 4.1%), but diarrhea was reported in more patients in the colchicine group (13.7% vs 7.3%). Serious adverse events were similar in both groups.

Tardif et al. (May 2021). Colchicine for Community-Treated Patients with COVID-19 (COLCORONA): A Phase 3, Randomised, Double-Blinded, Adaptive, Placebo-Controlled, Multicentre Trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/S2213-2600(21)00222-8